It is made in India and marketed in Indonesia under the brand name Covovax. Since the vaccine is stored at 2 to 8 degrees Celsius, existing vaccine supply channels can be used with conventional cold chains, which could increase access in hard-to-reach areas and increase vaccination rates across the country. The first shipments to Indonesia are expected to begin shortly.
Having access to a safe and highly effective vaccine coupled with ease of distribution should be instrumental in helping Indonesia control the current coronavirus outbreak. “We continue to work hard to ensure that the first protein-based Covid-19 vaccine in Indonesia is available to everyone waiting to arrive,” said a Novavax spokesman.